Fibronectin turnover in human mesangial cell cultures as affected by adriamycin

M Soose1, S Wenzel, H Stolte

  • 1Institute of Animal Physiology, Justus-Liebig-University Giessen, Germany.

Insights

Adriamycin (ADR) increases fibronectin (FN) in human mesangial cells, leading to extracellular accumulation and reduced cellular FN. This suggests ADR disrupts FN turnover, impacting extracellular matrix formation.

Area of Science:

  • Cell Biology
  • Pharmacology
  • Nephrology

Background:

  • Fibronectin (FN) is a crucial extracellular matrix (ECM) protein synthesized by human mesangial cells (HMC).
  • Altered FN turnover is implicated in kidney disease pathogenesis.
  • Adriamycin (ADR) is an anticancer drug with known nephrotoxic effects.

Purpose of the Study:

  • To investigate the effects of Adriamycin (ADR) on fibronectin (FN) turnover in human mesangial cells (HMC) in vitro.
  • To determine how ADR influences FN secretion, incorporation into the ECM, and degradation.

Main Methods:

  • HMC cultures were treated with varying concentrations of ADR (0.5-5 µg/ml).
  • Quantification of FN in culture medium and cells using radioisotopes and immunoprecipitation.
  • Analysis of FN incorporation into the ECM and pericellular fiber organization via immunofluorescence staining.
  • Assessment of FN degradation products in the culture medium.

Main Results:

  • ADR treatment led to a dose-dependent accumulation of FN in the culture medium, with a significant increase at 5 µg/ml.
  • Radioactive FN in the medium increased up to 50%, while intracellular radioactive FN decreased by 22%.
  • ADR (≥2 µg/ml) significantly enhanced FN incorporation into the ECM and expanded pericellular FN fibers.
  • A reduction in FN degradation products was observed in ADR-treated HMC cultures.

Conclusions:

  • ADR interferes with fibronectin (FN) turnover in human mesangial cells (HMC) in vitro.
  • ADR promotes extracellular FN accumulation and reduces intracellular FN levels.
  • These findings suggest ADR disrupts FN metabolism, potentially contributing to renal pathology observed in vivo.